Tear lipocalin muteins binding IL-4 R alpha
The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
1. A pharmaceutical composition comprising a mutein of human tear lipocalin having binding affinity to IL-4 receptor alpha, wherein the amino acid sequence of the mutein of the human tear lipocalin comprises the following amino acid substitutions: Arg 26→Ser, Glu 34→Asn, Met 55→Ala, and Ser 58→Lys, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin, and a pharmaceutically acceptable carrier or excipient.
2. The pharmaceutical composition of claim 1 , wherein the mutein further comprises the following amino acid substitutions: Asn 32→Val, Leu 56→Gln, and Glu 63→Lys, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
3. The pharmaceutical composition of claim 2 , wherein the mutein further comprises the following amino acid substitutions: Met 31→Ala, Leu 33→Tyr, Asp 80→Ser, Glu 104→Leu, His 106→Pro, and Lys 108→Gln, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
4. The pharmaceutical composition of claim 2 , wherein the mutein further comprises the following amino acid substitutions: Glu 27→Arg, Phe 28→Cys, Glu 30→Arg, Met 31→Ala, Leu 33→Tyr, Ile 57 Arg, Asp 80→Ser, Lys 83→Arg, Glu 104→Leu, Leu 105→Cys, His 106→Pro, and Lys 108→Gln, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
5. The pharmaceutical composition of claim 2 , wherein the mutein further comprises the following amino acid substitutions: Val 53→Phe, Val 64→Tyr, and Ala 66→Leu, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
6. The pharmaceutical composition of claim 2 , wherein the mutein further comprises the following amino acid substitutions: Arg 111→Pro, and Lys 114→Trp, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
7. The pharmaceutical composition of claim 2 , wherein the mutein further comprises the following amino acid substitutions: Cys 61→Trp, and Cys 153→Ser, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
8. The pharmaceutical composition of claim 2 , wherein the first four N-terminal amino acid residues with respect to the wild-type amino acid sequence positions of mature human tear lipocalin have been deleted.
9. The pharmaceutical composition of claim 2 , wherein the mutein further comprises the following amino acid substitutions: Cys 101→Ser, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
10. The pharmaceutical composition of claim 2 , wherein the mutein further comprises the following amino acid substitutions: Tyr 100→His, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
11. The pharmaceutical composition of claim 1 , wherein the mutein further comprises the following amino acid substitutions: Met 31→Ala, Leu 33→Tyr, Asp 80→Ser, Glu 104→Leu, His 106→Pro, and Lys 108→Gln, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
12. The pharmaceutical composition of claim 1 , wherein the mutein further comprises the following amino acid substitutions: Glu 27→Arg, Phe 28→Cys, Glu 30→Arg, Met 31→Ala, Leu 33→Tyr, Ile 57 Arg, Asp 80→Ser, Lys 83→Arg, Glu 104→Leu, Leu 105→Cys, His 106→Pro, and Lys 108→Gln, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
13. The pharmaceutical composition of claim 1 , wherein the mutein further comprises the following amino acid substitutions: Val 53→Phe, Val 64→Tyr, and Ala 66→Leu, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
14. The pharmaceutical composition of claim 1 , wherein the mutein further comprises the following amino acid substitutions: Arg 111→Pro, and Lys 114→Trp, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
15. The pharmaceutical composition of claim 1 , wherein the mutein further comprises the following amino acid substitutions: Cys 61→Trp, and Cys 153→Ser, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
16. The pharmaceutical composition of claim 1 , wherein the mutein comprises a mutated amino acid residue at each of sequence positions 26-28, 30-34, 53, 55-58, 63, 64, 66, 80, 83, 104-106, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
17. The pharmaceutical composition of claim 16 , wherein the first four N-terminal amino acid residues with respect to the wild-type amino acid sequence positions of mature human tear lipocalin have been deleted.
18. The pharmaceutical composition of claim 1 , wherein the mutein comprises, at sequence positions 26-28, 30-34, 53, 55-58, 63, 64, 66, 80, 83, 104-106 with respect to the wild-type amino acid sequence positions of mature human tear lipocalin, the same set of mutated amino acid residues that the mutein set forth in SEQ ID NO: 6 has at those respective positions.
19. The pharmaceutical composition of claim 18 , wherein the first four N-terminal amino acid residues with respect to the wild-type amino acid sequence positions of mature human tear lipocalin have been deleted.
20. The pharmaceutical composition of claim 1 , wherein the first four N-terminal amino acid residues with respect to the wild-type amino acid sequence positions of mature human tear lipocalin have been deleted.
21. The pharmaceutical composition of claim 1 , wherein the mutein is fused or conjugated at its N-terminus and/or its C-terminus to a protein or compound.
22. The pharmaceutical composition of claim 1 , wherein the mutein is fused or conjugated to a protein or compound that extends the half-life of the mutein.
23. The pharmaceutical composition of claim 1 , wherein the mutein further comprises the following amino acid substitutions: Cys 101→Ser, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
24. The pharmaceutical composition of claim 1 , wherein the mutein further comprises the following amino acid substitutions: Tyr 100→His, with respect to the wild-type amino acid sequence positions of mature human tear lipocalin.
25. The pharmaceutical composition of claim 1 , wherein the mutein comprises, at sequence positions 26-28, 30-34, 53, 55-58, 61, 63, 64, 66, 80, 83, 100, 101, 104-106, 108, 111, 114 and 153 with respect to the wild-type amino acid sequence positions of mature human tear lipocalin, the same set of mutated amino acid residues that the mutein set forth in SEQ ID NO: 6 has at those respective positions.